MeiraGTx Holdings plc Ordinary Shares

Day range

$9.05 – $9.33

Open

$9.24

Prev close

$9.21

Volume

302.26K

Market cap

$884.56M

Shares out

96.04M

P/E

11.20

P/S

2.23

P/B

4.10

P/FCF

84.51

ROE

36.6%

ROA

19.9%

Debt/Equity

0.56

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentSep 23, 2026

  “On September 22, 2026, the Board of Directors (the "Board") of MeiraGTx Holdings plc (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Alan M. Sebulsky to the Board as a Class I director, effective September 23, 2026, with a term that expires at the Company's 2028 annual meeting of shareholders.”

• Debt retirementJul 7, 2026

  On June 30, 2026, the Company redeemed in full all outstanding principal amounts under the notes issued pursuant to the Amended and Restated Notes Purchase Agreement and Guaranty, dated as of August 2, 2022... and paid accrued, but unpaid interest on such notes and certain other fees related to such redemption. Upon such redemption and payment, the Perceptive NPA terminated.

• Annual meeting resultsJun 15, 2026

  On June 11, 2026, MeiraGTx Holdings plc (the "Company") held its annual general meeting of shareholders (the "Annual Meeting"). A total of 75,326,022 of the Company's ordinary shares were present in person or represented by proxy at the Annual Meeting, representing approximately 81.4% of the Company's ordinary shares outstanding as of the April 21, 2026 record date. Following are the voting results for the proposals considered and voted upon at the Annual Meeting.

• Licensing agreementApr 24, 2026

  the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company, Hologen, HNAI and Hologen Neuro AI UK Limited, entered into the Collaboration and License Agreement (the 'Collaboration Agreement'), for the research, development, manufacture and commercialization of the Company's AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders

• Clinical trial resultsApr 16, 2026

  On April 16, 2026, the Company announced positive 3-year data from the Company's Phase 1 AQUAx clinical study of AAV-hAQP1 for the treatment of grade 2/3 radiation induced xerostomia. Treatment was observed to be safe and well tolerated at each dose tested with no dose-limiting toxicity or treatment-related serious adverse events.

Days to cover

5.0

Short interest

6M

Avg volume

1.19M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
  positiveThe Motley Fool· Jul 12, 2026
• Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
  negativeBenzinga· Apr 16, 2026
• MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
  positiveBenzinga· Apr 16, 2026
• Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration
  positiveBenzinga· Nov 10, 2025
• MeiraGTx Sales Jump 1,133 Percent
  neutralThe Motley Fool· Aug 14, 2025